ENB Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 6

ENB Therapeutics General Information

Description

Developer of small molecule inhibitors designed to overcome resistance towards cancer immunotherapy and reduce tumor growth. The company's inhibitors target the endothelial receptor to reverse the drug resistance that occurs in patients treated with immunotherapy, enabling physicians to reduce tumor growth and prolong survival in a variety of immunotherapy-resistant cancers.

Contact Information

Website
enbpharma.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 45-18 Court Square West
  • 6th floor, Long Island City
  • New York, NY 11101
  • United States
+1 (212)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 45-18 Court Square West
  • 6th floor, Long Island City
  • New York, NY 11101
  • United States
+1 (212)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ENB Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Secondary Transaction - Private 01-Apr-2026 Completed Clinical Trials - Phase 1
7. Later Stage VC 03-Oct-2023 Completed Clinical Trials - Phase 1
6. Later Stage VC 03-Jan-2022 Completed Clinical Trials - Phase 1
5. Later Stage VC 01-Mar-2021 Completed Clinical Trials - Phase 1
4. Later Stage VC (Series A) 27-Feb-2020 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series A) 12-Sep-2018 Completed Pre-Clinical Trials
2. Angel (individual) 25-Apr-2017 $110K $110K Completed Pre-Clinical Trials
1. Accelerator/Incubator 25-Apr-2016 Completed Pre-Clinical Trials
To view ENB Therapeutics’s complete valuation and funding history, request access »

ENB Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
To view ENB Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

ENB Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of small molecule inhibitors designed to overcome resistance towards cancer immunotherapy and reduce tumor gro
Drug Discovery
New York, NY
6 As of 2026

London, United Kingdom
 

Philadelphia, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ENB Therapeutics Competitors (117)

One of ENB Therapeutics’s 117 competitors is Orchard Therapeutics, a Formerly VC-backed company based in London, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Orchard Therapeutics Formerly VC-backed London, United Kingdom
Aro Biotherapeutics Venture Capital-Backed Philadelphia, PA
Verastem Formerly VC-backed Needham, MA
Cytokinetics Formerly VC-backed South San Francisco, CA
Kite Pharma Formerly VC-backed Santa Monica, CA
You’re viewing 5 of 117 competitors. Get the full list »

ENB Therapeutics Patents

ENB Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4608447-A1 Methods for treating cancers associated with etbr activation Pending 28-Oct-2022
US-20260130999-A1 Methods for treating cancers associated with etbr activation Pending 28-Oct-2022
WO-2024092239-A1 Methods for treating cancers associated with etbr activation Inactive 28-Oct-2022
US-20200268829-A1 Methods and compositions for inhibiting metastases of an endothelin b receptor expressing cancer Inactive 24-Mar-2020
US-20200289495-A1 Methods of inhibiting endothelin b receptor expressing tumor metastases Inactive 24-Mar-2020 A61K31/4025
To view ENB Therapeutics’s complete patent history, request access »

ENB Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ENB Therapeutics Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Avestria Ventures Venture Capital Minority
Alexandria Venture Investments Venture Capital Minority
BioAdvance Capital (Conshohocken) Venture Capital Minority
Remiges Ventures Venture Capital Minority
AJI Capital Venture Capital Minority
You’re viewing 5 of 6 investors. Get the full list »

ENB Therapeutics FAQs

  • When was ENB Therapeutics founded?

    ENB Therapeutics was founded in 2015.

  • Where is ENB Therapeutics headquartered?

    ENB Therapeutics is headquartered in New York, NY.

  • What is the size of ENB Therapeutics?

    ENB Therapeutics has 6 total employees.

  • What industry is ENB Therapeutics in?

    ENB Therapeutics’s primary industry is Drug Discovery.

  • Is ENB Therapeutics a private or public company?

    ENB Therapeutics is a Private company.

  • What is ENB Therapeutics’s current revenue?

    The current revenue for ENB Therapeutics is .

  • How much funding has ENB Therapeutics raised over time?

    ENB Therapeutics has raised $21.1M.

  • Who are ENB Therapeutics’s investors?

    Avestria Ventures, Alexandria Venture Investments, BioAdvance Capital (Conshohocken), Remiges Ventures, and AJI Capital are 5 of 6 investors who have invested in ENB Therapeutics.

  • Who are ENB Therapeutics’s competitors?

    Orchard Therapeutics, Aro Biotherapeutics, Verastem, Cytokinetics, and Kite Pharma are some of the 117 competitors of ENB Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process